#cvsi

[iwannrheonn]

@IwanRheon: Left Crawford a little gift in the bathroom, like any self-respecting Lord of the Rings fan would… I contemplated bunking in the cupboard and doing my best Gollum impression but I’m not here to put Mr Serkis to shame!  He’s going to shit bricks

[ @c-crawford ]

[iwannrheonn]

@IwanRheon: If one wasn’t bad enough!! I made Chace some company for when I’m out shopping… Can’t have him getting lonely. He’s only got a few hundred to find… #Where’sChace

[ @c-crawford ]

[itswallstreetpr]

CBD is Set to Come Roaring Back.. Four Stocks For the Win: CWBHF, GDET, CVSI, CGC

CBD is the cannabis-related play that deserves perhaps more excitement and interest from investors than its more well-known counterpart, marijuana. CBD is actually on pace to grow even bigger than pot because it holds the potential go mainstream across the board. But stocks in the space have taken a beating. The line between value play and value trap is a thin one. But this theme carries enough potential to leap over it in a single bound and likely on the near-term horizon as estimates of growth continue to be ratcheted higher. Today, we take a look at four of the most promising possibilities in the space: Charlotte's Web Holdings Inc (OTCMKTS:CWBHF), GD Entertainment & Technology Inc. (OTCMKTS:GDET), CV Sciences Inc (OTCMKTS:CVSI), and Canopy Growth Corp (NYSE:CGC).     Charlotte's Web Holdings Inc (OTCMKTS:CWBHF) is a good example of a company that has struggled to adapt to changing circumstances. But the company is working to expand fast, and raising capital to kickstart the action. Already, CWBHF represents the largest CBD pure-play in terms of total distribution footprint. To wit: The company just announced that it has entered into an agreement with Canaccord Genuity Corp, pursuant to which the Lead Underwriter, together with a syndicate of underwriters have agreed to purchase, on an underwritten basis, 5,000,000 units of the Company, at a price of C$13.25 per Unit, for aggregate gross proceeds to the Company of C$66,250,000. According to the release, net proceeds from the Offering will be used primarily to fund the Company's business development and for general working capital purposes. Charlotte's Web Holdings Inc (OTCMKTS:CWBHF) bills itself as a company that develops and distributes hemp-based cannabidiol (CBD) wellness products. Its products include CBD hemp oils, capsules, topicals, and pet products that feature CBD hemp oil extracts. Charlotte's Web Holdings, Inc. sells its products online as well as through distributors, and brick and mortar retailers. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. The company was incorporated in 2018 and is headquartered in Boulder, Colorado. Charlotte's Web Holdings, Inc. is the market leader in the production and distribution of innovative hemp-based cannabidiol wellness products. Founded by the Stanley Brothers, the Company's premium quality products start with proprietary hemp genetics that are responsibly manufactured into whole plant hemp extracts naturally containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids and other beneficial hemp compounds. Industrial hemp products are non-intoxicating. Charlotte's Web current product categories include tinctures (liquid products), capsules, topical, as well as pet products. Charlotte's Web hemp-based whole plant extracts are sold through select distributors, brick and mortar retailers, and online through the Company's website. The stock has suffered a bit of late, with shares of CWBHF taking a hit in recent action, down about -3% over the past week. Charlotte's Web Holdings Inc (OTCMKTS:CWBHF) pulled in sales of $33.1M in its last reported quarterly financials, representing top line growth of 42.7%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($46.3M against $31.2M).     GD Entertainment & Technology Inc. (OTCMKTS:GDET) is another stock that continues to look extremely cheap relative to the strong pace being set by the company in its core strategy, especially on the CBD side. The company recently opened a store for its CBD-based products subsidiary, The Greenery. The store, which is located at Palisades Center in West Nyack, New York, the second-largest shopping mall in the New York metropolitan area and the eighth-largest in the United States, was opened three weeks in time for Black Friday and the holiday shopping season. Now it is coming out and already talking about expansion in that space. Specifically, according to its most recent release, the company is entertaining a tangible offer to expand its “The Greenery” (TheGreeneryCo.com) CBD products physical retail exposure to a second, and larger, mall-based physical store location following positive branding and customer traffic data for its first mall-based physical store location. “Following an extremely positive experience at the kiosk level at Palisades Center, we have been approached by management at that location and given a priority access option to expand to an additional and larger space in another similar mall,” noted Anil Idnani, CEO of GDET. “The vast bulk of the potential market for CBD products has no idea that they need to navigate to some backwater ecommerce portal to buy CBD-based products. Instead, they are walking around popular shopping areas, browsing for something new and interesting to try – and CBD is that new and interesting possibility. The only way capture any piece of that market is to be in front of them, out in the world.” This is spectacular reasoning, and why we felt compelled to include the stock on this list. One other dimension that differentiates GDET in this list is diversification: it is also a fully-active and operating blockchain play. There are many potential synergies between these segments. But there is also the advantage of diversification of revenue streams, which may provide some cover if there is a further capitulatory washout in the hemp, cannabis, and CBD complex before the next leg higher in the space gets fully underway. We would also note that the company just announced a substantial reduction in its outstanding share count to lighten the load and send a shareholder-friendly signal to the market. “If we move forward with this second location, it will be because we have run the numbers and the store will more than pay for itself,” continued Idnani. “At this point, we believe we can be selective and expand as the right opportunities come along. But we also believe that this approach to distribution is on target for this market because we gain an edge in brand exposure that will pay priceless dividends down the road as this marketplace continues to go mainstream over coming quarters.”     CV Sciences Inc (OTCMKTS:CVSI) is a clear market leader in the CBD space in terms of brand recognition and distribution footprint. The company just announced a new distribution partnership with Southeastern Grocers, Inc. (SEG) with an initial launch at 115 Winn-Dixie stores in Florida and 37 BI-LO stores in South Carolina. PlusCBD™ Oil products are available at these stores as of November 3, 2019. According to the release, “CV Sciences’ new distribution partnership with SEG’s Winn-Dixie and BI-LO banners increases distribution and availability of a broad assortment of the Company’s best-selling PlusCBD™ Oil products, including ingestible dietary supplements. New distribution at select Winn-Dixie stores in Florida and BI-LO stores in South Carolina includes both topical products, such as PlusCBD™ Oil Extra Strength and Original Balm and PlusCBD™ Oil Roll-On, as well as PlusCBD™ Oil full spectrum hemp extract dietary supplements, including Gold Formula Softgels, Gold Formula Drops and Gummies, and Total Plant Complex Sprays.” CV Sciences Inc (OTCMKTS:CVSI) bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Moreover, CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. And the stock has been acting well over recent days, up something like 12% in that time. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -27%. CV Sciences Inc (OTCMKTS:CVSI) generated sales of $12.6M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -25.2% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($14.2M against $12.1M).     Canopy Growth Corp (NYSE:CGC) just announced that, effective January 14, 2020, David Klein has been appointed as the Company’s Chief Executive Officer. According to the release, “David brings a wealth of expertise to this role, having served in a number of senior leadership capacities over the past 14 years at Constellation Brands. His capabilities include extensive CPG and beverage alcohol industry experience, strong financial orientation, and experience operating in highly regulated markets in the U.S., Canada, Mexico and Europe. David is an experienced strategist with a deep understanding of how to build enduring consumer brands while leveraging operational scale across a dispersed production footprint. He is a strong leader with a proven track record of developing diverse and high performing teams.” “Canopy Growth sits at the forefront of one of the most exciting new market opportunities in our lifetime,” said Klein. “Thanks to the efforts of Mark and the entire team at Canopy Growth, no company is better positioned to win in the emerging cannabis market. I look forward to working with the team to build on the foundation that has been laid, to develop brands that strongly resonate with consumers, and to capture the market opportunity before us. Together we will drive sustainable, industry-leading growth that benefits employees, shareholders and the communities in which we operate.” Canopy Growth Corp (NYSE:CGC) engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. According to its own materials, the company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. In the company’s words, “Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.” This is also one of the most geographically diversified players in the cannabis space, with operations in 12 countries across five continents. And there has been plenty of PR work here. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. One of its most important divestitures and strategic interests is Canopy Rivers Inc., a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. The company works collaboratively with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. The company has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which the company believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. If you're long this stock, then you're liking how the stock has responded to the announcement. CGC shares have been moving higher over the past week overall, pushing about 10% to the upside on above average trading volume. Shares of the stock have powered higher over the past month, rallying roughly 5% in that time on strong overall action. Canopy Growth Corp (NYSE:CGC) pulled in sales of $76.6M in its last reported quarterly financials, representing top line growth of 228.4%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($2.8B against $425.8M). Read the full article

[itswallstreetpr]

Get Prepared for the Resurgence of the CBD Theme (CURLF, GWPH, HMPQ, CVSI)

Mainstream consumer adoption of CBD products represents a tailwind set to push overall CBD sector growth in the quarters ahead. This year alone is expected to show growth of over 900% in the space as mainstream big-brand retailers – such as Kroger’s, Walgreens, Walmart, Rite-Aid, and others – begin to carry CBD products in plain sight of browsing consumers.   This dynamic has helped raise awareness of the health benefits now being attributed to CBD, which has become known for its ability to help treat minor issues such as headaches and inflammation as well as contributing in care for more serious ailments, such as cancer, epilepsy, and multiple sclerosis.   Stocks in the space have been correcting in recent months, but these bargains won’t last forever.   As we near the next major leg of this growth boom, investors need to be prepared with a shopping list. Here are some interesting suggestions to consider: Curaleaf Holdings Inc (OTCMKTS:CURLF), GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), HempAmericana Inc (OTCMKTS:HMPQ), and CV Sciences Inc (OTCMKTS:CVSI)   Curaleaf Holdings Inc (OTCMKTS:CURLF) is a vertically integrated cannabis player that has started to move into the hemp-based CBD space in an aggressive fashion. The stock has been outperforming the broader hemp-cannabis-cbd complex in recent action, which is notable. The company just announced that it has opened its 27th dispensary in Florida at 3631 NW Federal Highway in Jensen Beach on Friday, November 15th. According to the release, “Curaleaf has the largest cannabis dispensary footprint in the US with 50 dispensaries across the country and continues to execute on its strategy of rapid expansion in Florida. The new 4,500 square foot location is accessible to patients from the Jensen Beach area, including the communities of Jupiter, Port St. Lucie, Stuart, Port Salerno and Palm City, and will offer a full range of premium quality medical cannabis products and private consultations by meticulously trained staff.” Curaleaf Holdings Inc (OTCMKTS:CURLF) operates a large number of dispensaries, 12 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Curaleaf, Inc. leverages its extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. Curaleaf is committed to being the industry's leading resource in education and advancement through research and advocacy. Curaleaf Inc.'s Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence. It cultivates, processes, markets, and/or dispenses a range of cannabis products in various operating markets, including flower, pre-rolls and flower pods, dry-herb vaporizer cartridges, concentrates for vaporizing, concentrates for dabbing, tinctures, lozenges, capsules, and edibles. And the stock has been acting well over recent days, up something like 11% in that time. "We have been hearing from patients about the need for a full-service medical cannabis center along the Martin County and St. Lucie County coast," said Joe Lusardi, Curaleaf CEO. "Curaleaf is proud to be the first dispensary in Jensen Beach, and we look forward to serving this community." Curaleaf Holdings Inc (OTCMKTS:CURLF) managed to rope in revenues totaling $64.9M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 0%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($140.3M against $64.1M).     GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has predicated its overall model on prescription CBD-based products. The company recently announced that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England. According to its release, “This represents the first-time any plant-derived cannabis-based medicine has been recommended by NICE for use on the NHS. Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Nabiximols, reviewed as part of NICE’s evaluation of cannabis-based medicinal products (CBMPs), has been considered cost effective for the treatment of spasticity due to multiple sclerosis.” GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) bills itself as a biopharmaceutical company that engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. We started off by noting that GWPH recently hit the wires with the announcement Even in light of this news, GWPH has had a rough past week of trading action, with shares sinking something like -5% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -17%. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) generated sales of $71.7M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 80.7% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($583.7M against $83.9M).     HempAmericana Inc (OTCMKTS:HMPQ) is more speculative, but could also be more promising given where the company is in its development path, and how cheap shares appear to be at present levels, with the transition from development stage to commercial stage operations just now underway. The first point to make here is how the company’s recent catalysts line up – the company just announced a big inventory build of $500K-plus in top quality hemp-based CBD products. Following that, the company released its ecommerce site and started to accumulate a sales force. Now, we see a number of interesting marketing and distribution steps being taken, including its recent signing of an LOI to with Smart Decision, Inc. to participate in a cutting edge algorithmic product recommendation system. This is important because the company has a strong manufacturing process with premium high-capacity supercritical CO2 CBD Oil extraction technology and a next-generation cultivation methodology. Once the inventory of the company’s high-grade product is assembled, all the remains is the distribution phase to monetize. HempAmericana Inc (OTCMKTS:HMPQ) is an emerging leader in the CBD products market. The Company owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility located in Augusta, Maine. This facility is armed with a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. The Company’s CBD oil business uses the brand designation, “Weed Got Oil”. HempAmericana also researches, develops, and sells products made of industrial hemp, including a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”. The company’s leadership is well-regarded, as noted by Adam Green, CEO of Smart Decision, in its most recent release: “We’re excited to have the opportunity to work with HempAmericana. Their operations and CBD manufacturing processes are both unique and truly impressive. Hemp Americana’s CEO, Sal Rosillo, is a visionary in both the Cannabis and CBD space. CBDSmartDecision.com will be the first company that has HempAmericana’s permission to recommend their product range on the affiliate level.” This is a highly speculative name because we haven’t seen big sales growth kick in yet. But, based on all appearances, that shift is underway now and we may be hearing a lot more for this stock soon.   CV Sciences Inc (OTCMKTS:CVSI) is, in many ways, the pure play spiritual leader of the CBD space due to its breakout parabolic move in 2018, catching the attention of the major financial media and really kicking off the CBD stock craze. But oh how the times have changed. The company just announced a new distribution partnership with Southeastern Grocers, Inc. (SEG) with an initial launch at 115 Winn-Dixie stores in Florida and 37 BI-LO stores in South Carolina. PlusCBD™ Oil products are available at these stores as of November 3, 2019. According to the release, “CV Sciences’ new distribution partnership with SEG’s Winn-Dixie and BI-LO banners increases distribution and availability of a broad assortment of the Company’s best-selling PlusCBD™ Oil products, including ingestible dietary supplements. New distribution at select Winn-Dixie stores in Florida and BI-LO stores in South Carolina includes both topical products, such as PlusCBD™ Oil Extra Strength and Original Balm and PlusCBD™ Oil Roll-On, as well as PlusCBD™ Oil full spectrum hemp extract dietary supplements, including Gold Formula Softgels, Gold Formula Drops and Gummies, and Total Plant Complex Sprays.” CV Sciences Inc (OTCMKTS:CVSI) bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. The stock has suffered a bit of late, with shares of CVSI taking a hit in recent action, down about -20% over the past week. CV Sciences Inc (OTCMKTS:CVSI) generated sales of $12.6M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -25.2% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($14.2M against $12.1M). Read the full article

[capital10x]

CV Sciences Stock Hammered Following Earnings

CV Sciences  fell in Wednesday trading as the company missed on both earnings and revenue. The San Diego-based CBD company lost about 25% of its value during Wednesday's trading session following the news. As a company that has missed estimates in three of the last four quarters, investors appear concerned. However, CV Sciences remains the second-largest hemp CBD company in the U.S., lagging only Charlotte’s Web Holdings . With a strong market position and massive overall growth in the industry, investors can make a strong case for buying this dip.

CV Sciences Missed On Earnings, Revenue

For its third quarter, the company reported a loss of one cent per share. This fell short of Wall Street expectations by two cents per share as analysts had predicted a profit of one cent per share. The company earned three cents per share in the year-ago quarter. Revenue also came up short as the company reported bringing in $12.6 million. This fell short of estimates by $6.01 million and represented a 7.4% drop on a year-over-year basis. The company blamed lower revenues on an uncertain regulatory environment for CBD as well as rising competition. For the drop in profits, they blamed reduced sales as well as increased investments in sales, marketing, and R&D. This led to a massive selloff. CVSI stock had closed at $2.10 per share before the report. However, in Wednesday trading, CV Sciences fell as low as $1.25 per share before staging a partial recovery. CVSI stock rose as high as $1.71 per share before pulling back in the afternoon. It closed the Wednesday trading session at $1.58 per share.

CVSI Grows Its Footprint Amid Competition

Given the strides CVSI stock made in recent months, the results appear baffling. During the quarter, the company’s store count rose from 4,591 to 5,435. These stores also include retailers such as Kroger , CVS Health , and The Vitamin Shoppe . Admittedly, competitors continue to enter the market. During the summer, Canopy Growth broke ground on a hemp industrial park in upstate New York. However, analysts expect the compound annual growth rate for the CBD market to reach 125.58% between 2019 and 2026. This growth rate should help to ensure growth, particularly to larger players such as CV Sciences.

Should I Buy CVSI Stock?

Despite the disappointing quarterly report, CV Sciences retains a strong market position. Granted, it would have helped to have some guidance for 2020. However, full-year guidance for the full year points to revenue between $55 million and $57 million. That still represents a substantial increase from $48 million in 2018. Moreover, unlike most cannabis companies, CVSI stock has a history of making profits. Consensus estimates point to a loss of five cents per share for 2019. However, they believe profits will return in 2020 as Wall Street forecasts earnings of nine cents per share. This would take the forward price-to-earnings (P/E) ratio to just 17.8. In a world where many marijuana stocks trade at a higher price-to-sales (P/S) ratio, this seems like a bargain. The P/S ratio for CVSI stock stands at 2.7. Hence, CVSI stock looks like a buy at these levels. Given the quick recovery from session lows, traders may have decided that they agree. Read the full article

[capital10x]

Is CV Sciences Stock Finally Ready to Move Higher?

CV Sciences (OTC: CVSI) stock spiked higher in Wednesday trading after landing another retailer, but will that become the catalyst CV Sciences needs to finally move higher? #marijuanastocks #potstocks $CVSI Read the full article

[capital10x]

Market Leadership Not Priced Into CVSI Stock

The prominence of CV Sciences  stock has risen in recent months. It received a considerable boost when the 2018 Farm Bill fully legalized hemp. The increased exposure from these sales played a role in Piper Jaffray initiating coverage on the stock with an overweight. However, CVSI stock remains on the over-the-counter market. Also, with its $330-plus million market cap and its base in the U.S., most investors have ignored it in favour of the largest Canadian players. Still, CVSI remains well-positioned to move higher as it grows with the emerging CBD industry.

Overweight Rating a Coup for CVSI Stock

In mid-August, Piper Jaffray analyst Michael Lavery placed a $5 price target on CVSI stock. That sent CV Science surging from the $3.10 per share level to as high as $3.89 per share over the next ten days. It has since fallen back below $3.30 per share. Certainly, attitudes have turned bearish across the cannabis industry. This has affected both CVSI and even top players such as Canopy Growth  and Aurora Cannabis . Profit estimates have also fallen for CVSI stock. The predicted 11 cents per share in annual earnings one month ago has fallen to a four-cent-per-share loss. Although Wall Street still expects a profitable fiscal 2020, earnings estimates have fallen to 13 cents per share, down from 22 cents per share recently. However, even with the pullback, the importance of this rating to the American cannabis industry cannot be overstated. In a market dominated by Canadian players and an industry hampered by a Schedule I designation, the overweight rating wins the company some needed recognition.

Market May Underrate Company Advantages

CVSI stock holds some advantages over most of its peers. The company operates in the hemp space. Thanks to the 2018 Farm Bill, hemp is the one form of cannabis that has become fully legal across the U.S. Without the restrictions of Schedule I, it can now operate across state and national boundaries with relatively little interference from the government. It has also secured sales agreements with the likes of Kroger , CVS Health , and more recently, Vitamin Shoppe . This has helped CV Sciences become the second-largest CBD company in the U.S. by revenue. With expected revenue growth of 42.6% this year and 49.4% in fiscal 2020, it should remain one of the top players in the industry. Moreover, at least for a marijuana equity, CVSI supports a reasonable valuation. It trades at only 5.6 times sales, well below the triple-digit sales multiples driving many Canadian marijuana equities. Furthermore, its forward price-to-earnings (PE) ratio of about 25.4 makes it enticing to investors looking for bargains.

Final Thoughts On CVSI Stock

CVSI appears well-positioned to deliver returns from both a market and a financial standpoint. The federal government legalization of hemp opened CV Sciences to CBD markets across the 50 states and the world. This has led to retailing agreements with prominent national chains and an upgrade from Piper Jaffray. CVSI stock has struggled in recent days with a selloff across the marijuana sector and the market in general. Short-term, it could continue to fall. However, with its reasonable valuation and massive growth, the longer-term future appears bright for CV Sciences. The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer. Read the full article

[capital10x]

CV Sciences Enjoys Strong Q2 Revenue Growth

CV Sciences, Inc. (OTC: CVSI) enjoyed 36% year-on-year revenue growth for the second quarter of 2019, while it also recorded 13% sequential growth. #marijuanastocks #potstocks $CVSI  Read the full article